{"id":1021558,"date":"2026-11-16T16:11:23","date_gmt":"2026-11-16T21:11:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\/"},"modified":"2026-11-16T16:11:23","modified_gmt":"2026-11-16T21:11:23","slug":"gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\/","title":{"rendered":"Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing<\/b><\/p>\n<p class=\"bwalignc\"><b><i>&#8211; Agreements Signed in Advance of Results from the Ebola Post-Exposure Prophylaxis Field Trial and Potential Regulatory Submissions &#8211;<\/i><\/b><\/p>\n<p class=\"bwalignc\"><b><i>&#8211; Existing Remdesivir Voluntary Licensing Agreements Also Being Expanded to Include Filovirus Disease &#8211;<\/i><\/b><\/p>\n<p>FOSTER CITY, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nGilead Sciences, Inc. (Nasdaq: GILD) today announced that it has signed royalty-free voluntary licensing agreements with three generic manufacturers to support potential future access to its investigational antiviral obeldesivir as post-exposure prophylaxis (PEP) for Ebola Bundibugyo virus disease (BVD). The agreements cover 127 primarily low- and lower-middle-income countries, consistent with the geographic scope of Gilead\u2019s existing voluntary licensing agreements for remdesivir for COVID-19 and include all African countries that have reported cases during the current Ebola BVD outbreak. The agreements<b \/>are intended to support manufacturing readiness, technology transfer and supply planning while the ongoing Ebola Post-Exposure Prophylaxis (EBO-PEP) field trial evaluates obeldesivir as PEP for Ebola BVD.<\/p>\n<p><b>Key Highlights<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nRoyalty-free voluntary licensing agreements with three generic manufacturers cover primarily low- and lower-middle-income countries and are intended to support potential future access to investigational obeldesivir.<\/p>\n<\/li>\n<li>\nEBO-PEP is a Phase 3 randomized, placebo-controlled trial being coordinated by <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Falima.ngo%2Fen%2Fpress-releases%2Fbundibugyo-ebola-virus-outbreak-launch-ebopep%2F&amp;esheet=54642124&amp;newsitemid=20261116572571&amp;lan=en-US&amp;anchor=ALIMA&amp;index=1&amp;md5=ea7e0c93b97d9e50fceb8baf47db8fa1\">ALIMA<\/a> and partners evaluating investigational obeldesivir as PEP for individuals at high risk of developing Ebola BVD.<\/p>\n<\/li>\n<li>\nGilead is updating its existing voluntary licensing agreements for remdesivir to include filovirus disease, supporting potential future access should results from the ongoing World Health Organization (WHO)-sponsored <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.who.int%2Fnews%2Fitem%2F02-07-2026-patient-enrolment-begins-in-a-scientific-trial-to-identify-the-first-effective-treatments-for-bundibugyo-virus-disease&amp;esheet=54642124&amp;newsitemid=20261116572571&amp;lan=en-US&amp;anchor=PARTNERS&amp;index=2&amp;md5=ed5ee4a5b10c0fe14062e3d75b41da9b\">PARTNERS<\/a> trial support its use as a treatment for Ebola BVD and pending potential regulatory approvals.<\/p>\n<\/li>\n<li>\nGilead recently donated more than 2,000 vials of remdesivir to Kenya for investigational use as treatment and PEP for people with confirmed Ebola BVD or individuals with a close contact exposure.<\/p>\n<\/li>\n<\/ul>\n<p>\n\u201cResponding to emerging infectious diseases, including Ebola virus disease, requires not only scientific innovation, but also early planning and collaboration to help ensure that effective medicines can reach the people who need them as quickly as possible,\u201d said Jaime McCoy, Vice President, Gilead Patient Solutions, Gilead Sciences. \u201cThese agreements reflect our commitment to preparing for future access while clinical research is ongoing, so that we are better positioned to respond if these investigational medicines demonstrate benefit and gain regulatory approval.\u201d<\/p>\n<p>\nThe manufacturers that have entered into voluntary licensing agreements with Gilead are Dr. Reddy\u2019s Laboratories, Eva Pharma and Ferozsons Laboratories. Technology transfer discussions are already underway, and agreements with additional manufacturers are under discussion. Under the agreements, the companies will be authorized to manufacture and supply obeldesivir in the licensed territory if supported by clinical data and applicable regulatory authorizations. Obeldesivir has demonstrated preclinical activity across multiple filoviruses but is not approved for the PEP of filovirus disease in any country.<\/p>\n<p>\nThese agreements are part of Gilead&#8217;s broader approach to outbreak preparedness, which includes clinical research, manufacturing and supply planning, technology transfer, and collaboration with governments, public health agencies and global health partners. As part of its response to the current Ebola BVD outbreak, Gilead has provided compassionate use donations of remdesivir to the Democratic Republic of the Congo (DRC), Uganda and Kenya totaling more than 38,000 vials.<\/p>\n<p><b><span class=\"bwuline\">About Obeldesivir<\/span><\/b><\/p>\n<p>\nObeldesivir is an investigational antiviral that has been evaluated in clinical trials for COVID-19 and respiratory syncytial virus (RSV) and has demonstrated preclinical activity across multiple filoviruses. It is currently being evaluated in the Ebola Post-Exposure Prophylaxis (EBO-PEP) trial, a partner-led Phase 3 randomized, placebo-controlled field trial evaluating the efficacy of obeldesivir as post-exposure prophylaxis (PEP) for individuals at high risk of developing Ebola Bundibugyo virus disease (BVD). Obeldesivir is not approved for the PEP of filovirus disease or for any indication in any country.<\/p>\n<p><b><span class=\"bwuline\">About Remdesivir<\/span><\/b><\/p>\n<p>\nRemdesivir is a nucleotide analog prodrug invented and developed by Gilead, building on more than a decade of the company\u2019s antiviral research. Remdesivir has broad-spectrum antiviral activity both in vitro and in animal models against multiple viral pathogens, including Marburg, Ebola, SARS, MERS and SARS-CoV-2, the virus that causes COVID-19.<\/p>\n<p>\nRemdesivir has been approved as a COVID-19 treatment in approximately 50 countries worldwide. To date, remdesivir has been made available to more than 14.5 million patients around the world, including more than 8.1 million people in middle- and low-income countries through Gilead\u2019s voluntary licensing program.<\/p>\n<p>\nThe clinical efficacy of remdesivir for the treatment of Ebola BVD has not been established. Remdesivir is currently not approved in any country for the treatment or prevention of Ebola BVD.<\/p>\n<p>\nFor more information about Gilead\u2019s commitment to global health, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.gilead.com%2F&amp;esheet=54642124&amp;newsitemid=20261116572571&amp;lan=en-US&amp;anchor=Gilead.com&amp;index=3&amp;md5=9e89c02c3509a43d80347335669b4c33\">Gilead.com<\/a>.<\/p>\n<p><b><span class=\"bwuline\">About Gilead Sciences<\/span><\/b><\/p>\n<p>\nGilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation.<\/p>\n<p>\nIn 2025, Gilead announced a $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness \u2013 while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.<\/p>\n<p><b><span class=\"bwuline\">Forward-Looking Statements<\/span><\/b><\/p>\n<p>\nThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead\u2019s ability to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical trials, including those involving obeldesivir and remdesivir (such as the partner-led EBO-PEP and PARTNERS trials); uncertainties relating to regulatory applications and related filing and approval timelines, including additional pending and potential applications for obeldesivir and remdesivir; the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; the possibility that Gilead may make a strategic decision to discontinue development of obeldesivir and remdesivir for indications currently under evaluation; Gilead\u2019s ability to effectively manage, execute and realize the anticipated benefits from the access strategy relating to obeldesivir and remdesivir, including voluntary licensing arrangements and external partnerships relating to obeldesivir and remdesivir; difficulties or unanticipated expenses in connection with such access strategy, licensing arrangements and partnerships; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead\u2019s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.<\/p>\n<p class=\"bwalignc\"><i>Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.<\/i><\/p>\n<p class=\"bwalignc\"><i>For more information about Gilead, please visit the company\u2019s website at <\/i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.gilead.com&amp;esheet=54642124&amp;newsitemid=20261116572571&amp;lan=en-US&amp;anchor=www.gilead.com&amp;index=4&amp;md5=efb8eb4b390f6c076993bfb7de649e40\"><i>www.gilead.com<\/i><\/a><i>, follow Gilead on X\/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences)<\/i><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116572571r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261116572571\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261116572571\/en\/<\/a><\/span><\/p>\n<p>\nPriscilla White, Media<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:public_affairs@gilead.com\">public_affairs@gilead.com<\/a><\/p>\n<p>\nJacquie Ross, Investors<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investor_relations@gilead.com\">investor_relations@gilead.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Africa United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Biotechnology Research Pharmaceutical Health Infectious Diseases Hospitals Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261116572571\/en\/778437\/3\/GCP_Primarylarge_1.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing &#8211; Agreements Signed in Advance of Results from the Ebola Post-Exposure Prophylaxis Field Trial and Potential Regulatory Submissions &#8211; &#8211; Existing Remdesivir Voluntary Licensing Agreements Also Being Expanded to Include Filovirus Disease &#8211; FOSTER CITY, Calif.&#8211;(BUSINESS WIRE)&#8211; Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has signed royalty-free voluntary licensing agreements with three generic manufacturers to support potential future access to its investigational antiviral obeldesivir as post-exposure prophylaxis (PEP) for Ebola Bundibugyo virus disease (BVD). The agreements cover 127 primarily low- and lower-middle-income countries, consistent with the geographic scope of Gilead\u2019s existing voluntary licensing agreements for remdesivir for COVID-19 and include all African countries that &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1021558","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing &#8211; Agreements Signed in Advance of Results from the Ebola Post-Exposure Prophylaxis Field Trial and Potential Regulatory Submissions &#8211; &#8211; Existing Remdesivir Voluntary Licensing Agreements Also Being Expanded to Include Filovirus Disease &#8211; FOSTER CITY, Calif.&#8211;(BUSINESS WIRE)&#8211; Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has signed royalty-free voluntary licensing agreements with three generic manufacturers to support potential future access to its investigational antiviral obeldesivir as post-exposure prophylaxis (PEP) for Ebola Bundibugyo virus disease (BVD). The agreements cover 127 primarily low- and lower-middle-income countries, consistent with the geographic scope of Gilead\u2019s existing voluntary licensing agreements for remdesivir for COVID-19 and include all African countries that &hellip; Continue reading &quot;Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T21:11:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116572571r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing\",\"datePublished\":\"2026-11-16T21:11:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\\\/\"},\"wordCount\":1281,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261116572571r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\\\/\",\"name\":\"Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261116572571r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-11-16T21:11:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261116572571r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261116572571r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\/","og_locale":"en_US","og_type":"article","og_title":"Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing - Market Newsdesk","og_description":"Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing &#8211; Agreements Signed in Advance of Results from the Ebola Post-Exposure Prophylaxis Field Trial and Potential Regulatory Submissions &#8211; &#8211; Existing Remdesivir Voluntary Licensing Agreements Also Being Expanded to Include Filovirus Disease &#8211; FOSTER CITY, Calif.&#8211;(BUSINESS WIRE)&#8211; Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has signed royalty-free voluntary licensing agreements with three generic manufacturers to support potential future access to its investigational antiviral obeldesivir as post-exposure prophylaxis (PEP) for Ebola Bundibugyo virus disease (BVD). The agreements cover 127 primarily low- and lower-middle-income countries, consistent with the geographic scope of Gilead\u2019s existing voluntary licensing agreements for remdesivir for COVID-19 and include all African countries that &hellip; Continue reading \"Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-16T21:11:23+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116572571r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing","datePublished":"2026-11-16T21:11:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\/"},"wordCount":1281,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116572571r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\/","name":"Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116572571r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-11-16T21:11:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116572571r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116572571r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021558","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1021558"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021558\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1021558"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1021558"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1021558"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}